CAS: 17575-22-3; (2R,3R,4S,6S)-6-(((2R,3S,4S,6S)-6-(((2R,3S,4S,6R)-6-(((3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-Dihydroxy-10,13-Dimethyl-17-(5-Oxo-2,5-Dihydrofuran-3-yl)Hexadecahydro-1H-Cyclopenta[a]Phenanthren-3-yl)Oxy)-4-Hydroxy-2-Methyltetrahydro-2H-Pyran-3-yl)Oxy)-4-Hy

上下游产品

毛花洋地黄苷a Lanatosid A 17575-20-1
毛花洋地黄苷b Lanatoside B 17575-21-2

📜毛花洋地黄苷a,毛花洋地黄苷b 反应生成毛花苷c
参考文献:Sterba,Jiri;Pitra,Josef
标题:Sterba,Jiri;Pitra,Josef

专利信息

专利号:US-6015808-A
优先权日:1993-08-20
标 题 :Synthesis of pharmaceutical compositions with lactams and β-lactams/oxo thia azabicyclo compounds
发明人：THIRUMALACHAR MANDAYAM JEERSAN; NARASIMHAN JR MANDAYAM JEERSAN
摘要:Pharmaceutical compositions with heretofore unknown and enhanced physical, chemical, and biological properties are prepared by combining known biologically active parent compounds with oxo thia azabicyclo compounds, such as lactam and beta -lactam compounds, capable of rapidly transporting the parent compounds in undegraded form to their target sites of action. A process for combining the parent compound with beta -lactam compounds consists of dissolving the parent compound in a polar solvent, adding a beta -lactam compound, incubating the resulting mixture, followed by drying, and subjecting the remaining solid material to solvent washing or extraction to further purify the new pharmaceutical composition. The new pharmaceutical composition possesses the biological and therapeutic activity of the parent compound and the barrier penetrating characteristics of the beta -lactam compound, which results in improved pharmacodynamics, including bioavailability, and an improved chemotherapeutic index, such that lower amounts of the parent may be used to avoid the toxic effects of the parent compound. Some of the new pharmaceutical compounds provide for the first time parent compounds in an orally administerable form.

专利号:US-6699676-B1
优先权日:1999-06-03
标题:Uses of ouabain and ouabain-like molecules in apoptosis related pathologies
发明人：ORLOV SERGEI N; HAMET PAVEL; TREMBLAY JOHANNE
权利人:CORP DU CT DE RECH DU CT HOSPI
摘要:Longterm elevation of the intracellular Na + /K + ratio inhibits macromolecule synthesis and proliferation in the majority of cell types studied so far, including vascular smooth muscle cells (VSMC). We report here that inhibition of the Na + ,K + pump in VSMC by ouabain or 1 hour preincubation in K + -depleted medium attenuated apoptosis triggered by serum withdrawal, staurosporine or okadaic acid. In the absence of ouabain, both DNA degradation and caspase-3 activation in VSMC undergoing apoptosis were insensitive to modification of the extracellular Na + /K + ratio as well as to hyperosmotic cell shrinkage. In contrast, protection of VSMC from apoptosis by ouabain was abolished under equimolar substitution of Na + o with K + o , showing that the anti apoptotic action of Na + ,K + pump inhibition was caused by inversion of the intracellular Na + /K + ratio. Unlike VSMC, the same level of increment of the [Na + ] i /[K + ] i ratio caused by 2 hours preincubation of Jurkat cells with ouabain did not affect chromatin cleavage and caspase-3 activity triggered by treatment with Fas ligand, staurosporine or hyperosmotic shrinkage. Thus, our results show for the first time that similarly to cell proliferation, maintenance of a physiologically low intracellular Na + /K + ratio is required for progression of VSMC apoptosis.

专利号:US-3963697-A
优先权日:1974-08-29
标题 :Labelled cardiotonic glycosides for use in radioimmunoassay
发明人：COOMBES ROBERT F
权利人:CURTIS NUCLEAR CORP
摘要:Disclosed are radioactive cardiotonic glycosides and a process of making such glycosides, the compounds being useful for radioimmunoassay of body fluids for cardiotonic glycoside content. n The novel synthesis comprises reaction of a hydroxyl group of the sugar with a dicarboxylic acid derivative such as a diacid, diacid anhydride or a diacyl halide and thereafter reacting the free carboxylic group with a compound which will undergo electrophilic substitution reactions. A radioactive isotope, preferably 125 I, is reacted via electrophilic substitution with the compound to form the radioactive cardiotonic glycoside.